Communiqués Burning Rock Biotech Limited

Actions

BNR

US12233L2060

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 16/07/2024			Varia. 5j.	Varia. 1 janv.
7,05 ^USD	-2,08 %		+27,72 %	-24,19 %

30/05	Burning Rock Biotech va travailler avec Bayer pour améliorer l'accès des patients aux médicaments de précision contre le cancer en Chine	MT
30/05	Bayer et Burning Rock Biotech Limited collaborent pour améliorer l'accès des patients aux médicaments de précision contre le cancer	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Burning Rock Regains Compliance with NASDAQ Minimum Bid Price Requirement	03/06	AQ
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines	30/05	AQ
Burning Rock Biotech : First Quarter 2024 Financial Results	29/05	PU
Burning Rock Reports First Quarter 2024 Financial Results	29/05	AQ
Burning Rock Schedules First Quarter of 2024 Earnings Release on May 29, 2024	23/05	AQ
Burning Rock Announces ADS Ratio Change to Be Effective on May 15, 2024	14/05	GL
BURG ROCK : Burning Rock ADS Ratio Change	09/05	PU
Burning Rock Publishes 2023 Annual Report on Form 20-F	29/04	GL
Burning Rock Biotech : 2023 Annual Report	29/04	PU
Burning Rock Announces ADS Ratio Change	26/04	GL
Burning Rock Announces ADS Ratio Change	26/04	AQ
Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results	28/03	GL
Burning Rock Announces Receipt of Notification from NASDAQ	04/01	GL
Burning Rock Announces Results of 2023 Annual General Meeting	20/12	GL
Burning Rock Reports Third Quarter 2023 Financial Results	30/11	GL
Burning Rock Announces 2023 Annual General Meeting to be Held on December 20, 2023	22/11	GL
Burning Rock Schedules Third Quarter of 2023 Earnings Release on November 30, 2023	21/11	GL
Burning Rock and Boehringer Ingelheim Achieved a Master Service Agreement in Oncology Companion Diagnostics	30/10/23	GL
Burning Rock Received Breakthrough Device Designation from China’s NMPA for its Multi-Cancer Early Detection Test	16/10/23	GL
Burning Rock's minimal residual disease (MRD) product supports advancement in early-stage non-small cell lung cancer treatment, with results published in the Cancer Cell	08/09/23	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Burning Rock Biotech Limited

Actions

BNR

US12233L2060

Communiqués

Filtres